Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394012 | 0.71 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL3155543 | 0.69 | SLC2A1 (0.54) | SLC2A1KCNH2 | |
| SCHEMBL3838900 | 0.66 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL4611499 | 0.65 | KCNH2 (0.49) | SLC2A1KCNH2 | |
| SCHEMBL3215036 | 0.65 | CYP19A1 (0.40) | SLC2A1KCNH2 | |
| SCHEMBL1723306 | 0.65 | KCNH2 (0.45) | SLC2A1KCNH2 | |
| SCHEMBL13070654 | 0.64 | SLC2A1 (0.54) | SLC2A1KCNH2 | |
| SCHEMBL2292976 | 0.62 | KCNH2 (0.39) | SLC2A1KCNH2 | |
| SCHEMBL2288096 | 0.62 | KCNH2 (0.39) | SLC2A1KCNH2 | |
| SCHEMBL3272153 | 0.62 | KCNH2 (0.48) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | SLC2A1 4630/4885KCNH2 784/4885LPAR1 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.